NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
LYNPARZA (olaparib) by AstraZeneca is poly(adp-ribose) polymerase inhibitors [moa]. First approved in 2017.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYNPARZA (olaparib) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor approved in 2017 for oncology indications. It works by inhibiting PARP enzymes, which repair DNA damage, making it effective in tumors with BRCA mutations or homologous recombination deficiency. The drug is currently at peak commercial lifecycle with strong patent protection extending to 2041.
Peak15.3 years to LOE
Peak-stage product with strong AstraZeneca backing and extended patent life suggests stable, well-resourced commercial teams focused on label expansion and market penetration.
Mechanism of Action
Poly(ADP-Ribose) Polymerase Inhibitors
Pharmacologic Class:
Poly(ADP-Ribose) Polymerase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
Started Dec 2025
50 enrolled
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Started Sep 2025
50 enrolled
Endometrial Cancer
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Started Aug 2025
33 enrolled
High Grade Serous Ovarian Cancer
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Started May 2025
150 enrolled
Endometrial Cancer
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Started Feb 2025
85 enrolled
Metastatic Castration-resistant Prostate Cancer
Worked on LYNPARZA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.